7月28日，三生制药（01530.HK）股价盘中大涨5.27%，引发市场关注。此轮涨势主要受益于公司与辉瑞（PFE）达成的重磅合作协议正式生效，以及多家券商上调公司目标价。
据悉，三生制药此前与辉瑞就PD-1/VEGF双特异性抗体（SSGJ-707）订立的全球许可协议已于7月24日起正式生效。根据协议，三生制药将获得12.5亿美元首付款，以及最高48亿美元的里程碑付款和双位数分级销售分成。此外，辉瑞还将以每股25.2港元认购三生制药约7.85亿港元股份。
市场分析认为，辉瑞计划加速推进SSGJ-707在全球的III期临床试验，这将显著提升该药物的开发进程。SSGJ-707被认为具有多重差异化特征，在ASCO公布的数据显示其在非小细胞肺癌治疗中展现出优秀的疗效。受此利好消息影响，多家券商纷纷上调三生制药的目标价。其中，招银国际将目标价上调33%至37.67港元，维持"买入"评级；花旗也将三生制药的目标价从21港元上调至36港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.